Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

Amanda Foskett, Christina Manley, Rebecca Naramore, Ira K Gordon, Bridget M Stewart, Chand Khanna The Oncology Service, LLC, Leesburg, VA, USA Abstract: Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The U...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Foskett A, Manley C, Naramore R, Gordon IK, Stewart BM, Khanna C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	sorafenib cancer tolerability study developmental therapeutics Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/a466842168cd4b3f8669b4a77ca74883
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a466842168cd4b3f8669b4a77ca74883
record_format	dspace
spelling	oai:doaj.org-article:a466842168cd4b3f8669b4a77ca748832021-12-02T06:11:39ZTolerability of oral sorafenib in pet dogs with a diagnosis of cancer2230-2034https://doaj.org/article/a466842168cd4b3f8669b4a77ca748832017-12-01T00:00:00Zhttps://www.dovepress.com/tolerability-of-oral-sorafenib-in-pet-dogs-with-a-diagnosis-of-cancer-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034Amanda Foskett, Christina Manley, Rebecca Naramore, Ira K Gordon, Bridget M Stewart, Chand Khanna The Oncology Service, LLC, Leesburg, VA, USA Abstract: Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The US Food and Drug Administration approved sorafenib in human patients with liver, thyroid, or renal carcinoma. The aim of this study was to help guide future pharmacokinetic (PK) studies of sorafenib in dogs with a cancer diagnosis. Client-owned dogs were eligible if they had a cytologic or histologic diagnosis of cancer. Patients were enrolled at escalating doses of sorafenib. Patients were evaluable for the study if they received at least one dose of sorafenib and presented 1 week later for a follow-up examination, blood work, and assessment of drug tolerability. The goal of this study was not to define a maximum tolerated dose as may be reasonable in conventional cytotoxic chemotherapy drugs, but rather to describe the tolerability of this drug in dogs with a cancer diagnosis, as a prequel to future sorafenib PK studies. No patients in the study had any evidence of adverse events that were attributable to sorafenib. Doses of 3 mg/kg were well tolerated and associated with a suggestion of clinical activity, supportive of future PK, and pharmacodynamic analysis. Such future studies are recommended at this dose to define the associated exposure achieved and determine a reasonable schedule for sorafenib administration. Keywords: sorafenib, cancer, tolerability study, developmental therapeutics Foskett AManley CNaramore RGordon IKStewart BMKhanna CDove Medical Pressarticlesorafenibcancertolerability studydevelopmental therapeuticsVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol Volume 8, Pp 97-102 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	sorafenib cancer tolerability study developmental therapeutics Veterinary medicine SF600-1100
spellingShingle	sorafenib cancer tolerability study developmental therapeutics Veterinary medicine SF600-1100 Foskett A Manley C Naramore R Gordon IK Stewart BM Khanna C Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
description	Amanda Foskett, Christina Manley, Rebecca Naramore, Ira K Gordon, Bridget M Stewart, Chand Khanna The Oncology Service, LLC, Leesburg, VA, USA Abstract: Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The US Food and Drug Administration approved sorafenib in human patients with liver, thyroid, or renal carcinoma. The aim of this study was to help guide future pharmacokinetic (PK) studies of sorafenib in dogs with a cancer diagnosis. Client-owned dogs were eligible if they had a cytologic or histologic diagnosis of cancer. Patients were enrolled at escalating doses of sorafenib. Patients were evaluable for the study if they received at least one dose of sorafenib and presented 1 week later for a follow-up examination, blood work, and assessment of drug tolerability. The goal of this study was not to define a maximum tolerated dose as may be reasonable in conventional cytotoxic chemotherapy drugs, but rather to describe the tolerability of this drug in dogs with a cancer diagnosis, as a prequel to future sorafenib PK studies. No patients in the study had any evidence of adverse events that were attributable to sorafenib. Doses of 3 mg/kg were well tolerated and associated with a suggestion of clinical activity, supportive of future PK, and pharmacodynamic analysis. Such future studies are recommended at this dose to define the associated exposure achieved and determine a reasonable schedule for sorafenib administration. Keywords: sorafenib, cancer, tolerability study, developmental therapeutics
format	article
author	Foskett A Manley C Naramore R Gordon IK Stewart BM Khanna C
author_facet	Foskett A Manley C Naramore R Gordon IK Stewart BM Khanna C
author_sort	Foskett A
title	Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
title_short	Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
title_full	Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
title_fullStr	Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
title_full_unstemmed	Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
title_sort	tolerability of oral sorafenib in pet dogs with a diagnosis of cancer
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/a466842168cd4b3f8669b4a77ca74883
work_keys_str_mv	AT fosketta tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer AT manleyc tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer AT naramorer tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer AT gordonik tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer AT stewartbm tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer AT khannac tolerabilityoforalsorafenibinpetdogswithadiagnosisofcancer
_version_	1718400067203760128

Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

Ejemplares similares